BioSpace News Archive

“Bavencio is the first immunotherapy to demonstrate in a clinical trial a statistically significant improvement in overall survival as a first-line treatment for patients with advanced urothelial carcinoma,” said Chris Boshoff, chief development officer, Oncology, Pfizer Global Product Development.

The three-way deal is focused on the development of small molecule inhibitors against several drug targets, including the KRAS oncogene, which are currently being investigated for the treatment of cancer.

Amarantus Bioscience Holdings, Inc. announced that it has completed an exclusive worldwide sublicense agreement for development rights of Cutanogen Corporation’s and MANF Therapeutics, Inc.’s pipelines to Emerald Organic Products, a diversified cannabidiol -focused health sciences company.

Polygon Company, a leading producer of composite tubing, bearings, and cylinders, announces that it will be exhibiting its high-performance PolyMed® Composite Tubing for surgical applications at Medical Design & Manufacturing West from February 11-13 at the Anaheim Convention Center in Anaheim, California, in Booth #2246.

The Novo Holdings REPAIR Impact Fund announced a EUR 7 million investment in Mutabilis, a company developing novel antibacterials against Gram-negative infections based near Paris, France.

Part of that exponential approval growth is due to a greater understanding of the development process and are pairing the right antibodies with the appropriate toxic agents.

Biomedical engineers at the University of Minnesota conducted a first-of-its-kind study on molecular interactions.

A recent market report by Signify Research found that venture capital investment for AI in drug development and clinical trials had reached $5.2 billion, although it pointed to investments slowing down in 2019 with only four new companies being formed.

Whether you’ve had your review or are gearing up for it, asking career-related questions can help increase productivity. These questions can help you set new year goals.

Three months after it won approval in type 2 diabetes, AstraZeneca’s Farxiga is eying potential regulatory win as a treatment in heart failure patients.